141 related articles for article (PubMed ID: 24258313)
1. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial.
Verhagen PC; Wildhagen MF; Verkerk AM; Vjaters E; Pagi H; Kukk L; Bratus D; Fiala R; Bangma CH; Schröder FH; Mickisch GH
World J Urol; 2014 Oct; 32(5):1287-94. PubMed ID: 24258313
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
3. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C
Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949
[TBL] [Abstract][Full Text] [Related]
4. Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
Debruyne FJ; Murray R; Fradet Y; Johansson JE; Tyrrell C; Boccardo F; Denis L; Marberger JM; Brune D; Rassweiler J; Vangeneugden T; Bruynseels J; Janssens M; De Porre P
Urology; 1998 Jul; 52(1):72-81. PubMed ID: 9671874
[TBL] [Abstract][Full Text] [Related]
5. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
[TBL] [Abstract][Full Text] [Related]
6. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
[TBL] [Abstract][Full Text] [Related]
7. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
de Voogt HJ; Studer U; Schröder FH; Klijn JG; de Pauw M; Sylvester R
Eur Urol; 1998; 33(2):152-8. PubMed ID: 9519356
[TBL] [Abstract][Full Text] [Related]
8. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
9. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of intermittent androgen deprivation in advanced prostate cancer.
Horwich A; Huddart RA; Gadd J; Boyd PJ; Hetherington JW; Whelan P; Dearnaley DP
Br J Urol; 1998 Jan; 81(1):96-9. PubMed ID: 9467483
[TBL] [Abstract][Full Text] [Related]
11. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
12. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
13. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Sylvester RJ; Denis L; de Voogt H
Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
Thorpe SC; Azmatullah S; Fellows GJ; Gingell JC; O'Boyle PJ
Eur Urol; 1996; 29(1):47-54. PubMed ID: 8821690
[TBL] [Abstract][Full Text] [Related]
15. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.
Klotz LH; Goldenberg SL; Jewett MA; Fradet Y; Nam R; Barkin J; Chin J; Chatterjee S;
J Urol; 2003 Sep; 170(3):791-4. PubMed ID: 12913699
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
17. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
18. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.
Klotz LH; Goldenberg SL; Jewett M; Barkin J; Chetner M; Fradet Y; Chin J; Laplante S
Urology; 1999 Apr; 53(4):757-63. PubMed ID: 10197852
[TBL] [Abstract][Full Text] [Related]
19. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
[TBL] [Abstract][Full Text] [Related]
20. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
de Voogt HJ; Klijn JG; Studer U; Schröder F; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):965-9. PubMed ID: 2149509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
